136 related articles for article (PubMed ID: 34071914)
21. Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo.
Holzleitner N; Günther T; Beck R; Lapa C; Wester HJ
Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558917
[TBL] [Abstract][Full Text] [Related]
22. Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions.
Klingler M; Hörmann AA; Guggenberg EV
Curr Med Chem; 2020; 27(41):7112-7132. PubMed ID: 32586246
[TBL] [Abstract][Full Text] [Related]
23.
Rangger C; Klingler M; Balogh L; Pöstényi Z; Polyak A; Pawlak D; Mikołajczak R; von Guggenberg E
Mol Pharm; 2017 Sep; 14(9):3045-3058. PubMed ID: 28728415
[TBL] [Abstract][Full Text] [Related]
24. Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs.
Holzleitner N; Fischer S; Maniyankerikalam I; Beck R; Lapa C; Wester HJ; Günther T
EJNMMI Res; 2024 Mar; 14(1):23. PubMed ID: 38429609
[TBL] [Abstract][Full Text] [Related]
25. Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon.
Kaloudi A; Nock BA; Lymperis E; Krenning EP; de Jong M; Maina T
Cancer Biother Radiopharm; 2016 Feb; 31(1):20-8. PubMed ID: 26844849
[TBL] [Abstract][Full Text] [Related]
26. Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue.
Pfister J; Summer D; Rangger C; Petrik M; von Guggenberg E; Minazzi P; Giovenzana GB; Aloj L; Decristoforo C
EJNMMI Res; 2015 Dec; 5(1):74. PubMed ID: 26669693
[TBL] [Abstract][Full Text] [Related]
27. Development of Highly Potent Clinical Candidates for Theranostic Applications against Cholecystokinin-2 Receptor Positive Cancers.
Corlett A; Pinson JA; Rahimi MN; Zuylekom JV; Cullinane C; Blyth B; Thompson PE; Hutton CA; Roselt PD; Haskali MB
J Med Chem; 2023 Aug; 66(15):10289-10303. PubMed ID: 37493526
[TBL] [Abstract][Full Text] [Related]
28. Elucidating the Structure-Activity Relationship of the Pentaglutamic Acid Sequence of Minigastrin with Cholecystokinin Receptor Subtype 2.
Ritler A; Shoshan MS; Deupi X; Wilhelm P; Schibli R; Wennemers H; Béhé M
Bioconjug Chem; 2019 Mar; 30(3):657-666. PubMed ID: 30608664
[TBL] [Abstract][Full Text] [Related]
29. Amide-to-Triazole Switch in Somatostatin-14-Based Radioligands: Impact on Receptor Affinity and In Vivo Stability.
Guarrochena X; Kanellopoulos P; Stingeder A; Rečnik LM; Feiner IVJ; Brandt M; Kandioller W; Maina T; Nock BA; Mindt TL
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543286
[TBL] [Abstract][Full Text] [Related]
30. Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.
Maina T; Kaloudi A; Valverde IE; Mindt TL; Nock BA
Nucl Med Biol; 2017 Sep; 52():57-62. PubMed ID: 28636973
[TBL] [Abstract][Full Text] [Related]
31. In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111)In-radioligands.
Kaloudi A; Nock BA; Lymperis E; Sallegger W; Krenning EP; de Jong M; Maina T
Nucl Med Biol; 2015 Nov; 42(11):824-32. PubMed ID: 26300210
[TBL] [Abstract][Full Text] [Related]
32. Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK
Nock BA; Kanellopoulos P; Chepurny OG; Rouchota M; Loudos G; Holz GG; Krenning EP; Maina T
Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35336041
[TBL] [Abstract][Full Text] [Related]
33. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
34. Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals.
von Guggenberg E; Kolenc P; Rottenburger C; Mikołajczak R; Hubalewska-Dydejczyk A
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830930
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers.
Wayua C; Low PS
J Nucl Med; 2015 Jan; 56(1):113-9. PubMed ID: 25500824
[TBL] [Abstract][Full Text] [Related]
36. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison.
Tornesello AL; Aurilio M; Accardo A; Tarallo L; Barbieri A; Arra C; Tesauro D; Morelli G; Aloj L
J Pept Sci; 2011 May; 17(5):405-12. PubMed ID: 21351319
[TBL] [Abstract][Full Text] [Related]
37. Probing the Backbone Function of Tumor Targeting Peptides by an Amide-to-Triazole Substitution Strategy.
Valverde IE; Vomstein S; Fischer CA; Mascarin A; Mindt TL
J Med Chem; 2015 Sep; 58(18):7475-84. PubMed ID: 26309061
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
39. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
[TBL] [Abstract][Full Text] [Related]
40. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
